TuHURA Biosciences merges with Kintara Therapeutics, forming TuHURA Biosciences, Inc., and plans a Phase 3 trial for cancer immunotherapy resistance in 2025.

TuHURA Biosciences has finalized its merger with Kintara Therapeutics, now operating as TuHURA Biosciences, Inc. The company aims to advance technologies to combat resistance to cancer immunotherapies, with a Phase 3 trial for Merkel Cell carcinoma planned for 2025 under FDA Special Protocol Assessment. The merger is supported by $31 million in funding, and TuHURA's stock will begin trading on Nasdaq as "HURA" on October 18, 2024.

October 17, 2024
6 Articles

Further Reading